Gottlieb's Pfizer Board Seat: Quick, Bold, But Not Unusual For An Ex-Commish
Executive Summary
While nearly all former FDA commissioners have served on the board of a pharmaceutical company, a Pink Sheet analysis finds that many have also served on the board of non-profit institutions after leaving public service.
You may also be interested in...
Flagship's $3.37bn Fund To Grow First-In-Category Firms
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
Graft Trail: Top Level Indian Regulatory Official Arrested
The arrest of India's deputy drugs controller creates shock waves and indicates an intent to clamp down on graft at any level, say industry experts.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.